Faro AI Raises $37.3M for AI Agents in Clinical Trials

Faro AI, a San Diego-based company building structured data infrastructure for clinical drug development, raised $37.3 million in Series B financing, co-led by Merck Global Health Innovation Fund and S32, according to the company's own announcement of the round. All existing investors participated, including General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, and Zetta, alongside new investor Ankona Capital.

Faro's focus fills a notable gap in how AI investment has concentrated across pharmaceutical development so far. Most AI drug discovery capital has gone toward molecule design specifically, with Isomorphic Labs raising $2.1 billion and Chai Discovery raising $400 million to help find drug candidates faster and cheaper, according to WOWTALE's analysis of the funding landscape. But even after a promising molecule is identified, the road from first-in-human studies to regulatory approval runs for years, and far fewer companies have targeted that far longer, more operationally complex stretch of the process.

Faro builds proprietary clinical development data models that translate complex scientific, medical, regulatory, and operational concepts into structured, machine-readable intent, letting AI agents reason across clinical development processes and automate workflows while maintaining the context and human oversight development teams require. According to Citybiz's reporting on the round, protocols and other clinical documents can be generated from this underlying foundation, but document generation represents only one of many outputs and workflows the models support.

Faro AI's Funding History

A genuinely notable detail in this raise is who's co-leading it. Merck Global Health Innovation Fund taking a co-lead position means capital is arriving directly from the strategic investment arm of a company that would also become Faro's customer, according to WOWTALE's analysis, a meaningful validation signal distinct from purely financial venture backing. Merck Global Health Innovation Fund principal Mike Morgan framed the investment thesis directly: "By saving time and improving quality, agentic AI has the potential to transform the way the biopharmaceutical industry conducts clinical development."

Faro co-founder and CEO Scott Chetham was explicit about what differentiates the company's ambitions from simpler AI content tools. "Our customers want to use AI agents not simply to generate content, but to understand development intent, reason across these processes, and automate more of the work required to move a program forward," Chetham said, according to Citybiz's reporting. In the company's own blog post announcing the round, Chetham elaborated on the underlying complexity: "Clinical development is built on thousands of interconnected scientific, medical, regulatory and operational decisions. A change in one part of a study can affect eligibility criteria, site operations, data collection, statistical analysis, regulatory documentation and downstream systems," according to Faro's own blog.

Faro's approach connects directly to the broader pattern we've tracked closely this month of AI agents moving into genuinely high-stakes, regulated workflows requiring both reasoning and human oversight, including Twin1 AI's digital twin platform for professional expertise and the enterprise AI security infrastructure race we've covered extensively this month. Faro's specific customer base, six of the world's ten largest pharmaceutical companies, gives the company genuine breadth of experience modeling clinical development programs across a wide range of therapeutic areas and study designs.

Faro's raise is worth understanding for any business in pharmaceuticals, biotechnology, or clinical research evaluating AI adoption specifically for regulated, high-stakes operational workflows rather than pure content generation. The distinction Chetham draws, between AI that generates documents versus AI that genuinely reasons across interconnected regulatory and operational decisions, is a useful framework for evaluating AI vendors in any complex, compliance-heavy industry.

For businesses in healthcare and life sciences specifically, Merck's strategic co-lead position on this round is worth watching as a signal that major pharmaceutical companies see genuine, near-term commercial value in agentic AI for clinical operations, not just molecule discovery, an area that's received considerably less attention and investment to date.

How much funding did Faro AI raise?
Faro AI raised $37.3 million in Series B financing, co-led by Merck Global Health Innovation Fund and S32, bringing the company's total funding raised since 2021 to roughly $76 million.

What does Faro AI's platform actually do?
Faro builds structured clinical development data models that let AI agents reason across complex scientific, medical, regulatory, and operational decisions throughout the drug development process, automating workflows while maintaining human oversight.

How widely is Faro AI's platform used in the pharmaceutical industry?
Faro's platform is currently used by six of the world's ten largest pharmaceutical companies, giving the company broad experience across multiple therapeutic areas and clinical study designs.

Faro AI raised $37.3 million in Series B financing, co-led by Merck Global Health Innovation Fund and S32, to expand its AI agent platform for clinical drug development, an area that has received far less AI investment than molecule discovery despite representing years of a drug's development timeline. The company's structured data models let AI agents reason across interconnected clinical, regulatory, and operational decisions rather than simply generating documents, with the platform already used by six of the world's ten largest pharmaceutical companies. Merck's own venture fund co-leading the round signals genuine strategic validation from a company that would also become a customer of the technology.